Education
About Us
Working with TipRanks
Follow Us
Beam Therapeutics (BEAM)
NASDAQ:BEAM
Total Valuation
Beam Therapeutics has a market cap or net worth of $1.67B. The enterprise value is $2.68B.
Market Cap$1.67B
Enterprise Value$2.68B
Share Statistics
Beam Therapeutics has 100,557,090 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding100,557,090
Owned by Insiders1.60%
Owned by Institutions50.03%
Financial Efficiency
Beam Therapeutics’s return on equity (ROE) is -0.51 and return on invested capital (ROIC) is -44.44%.
Return on Equity (ROE)-0.51
Return on Assets (ROA)-0.34
Return on Invested Capital (ROIC)-44.44%
Return on Capital Employed (ROCE)-0.45
Revenue Per Employee161.62K
Profits Per Employee-958.63K
Employee Count393
Asset Turnover0.06
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Beam Therapeutics is -5.42. Beam Therapeutics’s PEG ratio is 0.36.
PE Ratio-5.42
PS Ratio0.00
PB Ratio3.73
Price to Fair Value2.78
Price to FCF-103.63
Price to Operating Cash Flow121.56
PEG Ratio0.36
Income Statement
In the last 12 months, Beam Therapeutics had revenue of 63.52M and earned -376.74M in profits. Earnings per share was -4.58.
Revenue63.52M
Gross Profit41.59M
Operating Income-415.57M
Pretax Income-376.70M
Net Income-376.74M
EBITDA-383.98M
Earnings Per Share (EPS)-4.58
Cash Flow
In the last 12 months, operating cash flow was -351.38M and capital expenditures -9.57M, giving a free cash flow of -360.96M billion.
Operating Cash Flow-351.38M
Free Cash Flow-360.96M
Free Cash Flow per Share-3.59
Dividends & Yields
Beam Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.35
52-Week Price Change-28.05%
50-Day Moving Average17.53
200-Day Moving Average23.49
Relative Strength Index (RSI)43.12
Average Volume (3m)1.87M
Important Dates
Beam Therapeutics upcoming earnings date is Aug 12, 2025, TBA Not Confirmed.
Last Earnings DateMay 6, 2025
Next Earnings DateAug 12, 2025
Ex-Dividend Date―
Financial Position
Beam Therapeutics as a current ratio of 4.82, with Debt / Equity ratio of 24.41%
Current Ratio4.82
Quick Ratio4.82
Debt to Market Cap<0.01
Net Debt to EBITDA0.31
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Beam Therapeutics has paid 39.00K in taxes.
Income Tax39.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Beam Therapeutics EV to EBITDA ratio is -5.00, with an EV/FCF ratio of -5.39.
EV to Sales30.24
EV to EBITDA-5.00
EV to Free Cash Flow-5.39
EV to Operating Cash Flow-5.53
Balance Sheet
Beam Therapeutics has $1.22B in cash and marketable securities with $158.13M in debt, giving a net cash position of -$1.06B billion.
Cash & Marketable Securities$1.22B
Total Debt$158.13M
Net Cash-$1.06B
Net Cash Per Share-$10.56
Tangible Book Value Per Share$8.91
Margins
Gross margin is 62.94%, with operating margin of -654.25%, and net profit margin of -593.13%.
Gross Margin62.94%
Operating Margin-654.25%
Pretax Margin-593.06%
Net Profit Margin-593.13%
EBITDA Margin-604.51%
EBIT Margin-654.25%
Analyst Forecast
The average price target for Beam Therapeutics is $43.42, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$43.42
Price Target Upside161.25% Upside
Analyst ConsensusStrong Buy
Analyst Count14
Revenue Growth Forecast-82.38%
EPS Growth Forecast-164.76%